RKVT.F Stock Overview
A biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rakovina Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.06 |
| 52 Week High | CA$0.06 |
| 52 Week Low | CA$0.06 |
| Beta | 0.23 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| RKVT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.7% | 1.1% |
| 1Y | n/a | 6.9% | 22.5% |
Return vs Industry: Insufficient data to determine how RKVT.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how RKVT.F performed against the US Market.
Price Volatility
| RKVT.F volatility | |
|---|---|
| RKVT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: RKVT.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RKVT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Mads Daugaard | www.rakovinatherapeutics.com |
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. Its preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada.
Rakovina Therapeutics Inc. Fundamentals Summary
| RKVT.F fundamental statistics | |
|---|---|
| Market cap | US$5.64m |
| Earnings (TTM) | -US$1.99m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs RKVT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RKVT.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.72m |
| Earnings | -CA$2.72m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.039 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 46.0% |
How did RKVT.F perform over the long term?
See historical performance and comparison